{"transactions":[{"id":2056380,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-11T16:16:50.000Z","date":"2023-01-11","kind":"disposition_to_issuer","acquired":false,"shares":11904,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, was exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the \"Merger\"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, was exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership of these securities and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. The Reporting Person is an employee of Blackstone Inc. or one of its affiliates (\"Blackstone\"). Pursuant to arrangements between the Reporting Person and Blackstone, the Reporting Person is required to transfer to Blackstone any and all compensation received in connection with his directorship for any company Blackstone invests in or advises."}],"balance_after":0,"derivative":{"exercise_price":15.65,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0000899243-23-001599","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1249153/000089924323001599/doc4.xml","form_type":"4"}},{"id":2056379,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-11T16:16:50.000Z","date":"2023-01-11","kind":"other","acquired":false,"shares":26095,"price":36,"value":939420.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-001599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249153/000089924323001599/doc4.xml","form_type":"4"}},{"id":2244295,"issuer":{"id":15490,"kind":"organization","name":"Imago BioSciences, Inc.","symbol":"IMGO"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T16:38:45.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":11904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2023 of the Issuer's stockholders, assuming continuous service as a director until such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of these securities and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. The Reporting Person is an employee of Blackstone Inc. or one of its Affiliates (\"Blackstone\"). Pursuant to arrangements between the Reporting Person and Blackstone, the Reporting Person is required to transfer to Blackstone any and all compensation received in connection with his directorship for any company Blackstone invests in or advises."}],"balance_after":0,"derivative":{"exercise_price":15.65,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":11904},"source":{"system":"sec-edgar","filing":"0001567619-22-012284","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1249153/000156761922012284/doc1.xml","form_type":"4"}},{"id":3180692,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-04-07T12:26:15.000Z","date":"2020-04-07","kind":"disposition_to_issuer","acquired":false,"shares":10322,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. (\"Gilead\") and Toro Merger Sub, Inc. (\"Purchaser\") (the \"Merger\"), upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the \"Offer to Purchase\") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which provided for vesting on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date, was canceled in the Merger in exchange for a cash payment of $874,170.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option."}],"balance_after":0,"derivative":{"exercise_price":10.81,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":10322},"source":{"system":"sec-edgar","filing":"0001209191-20-023722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919120023722/doc4.xml","form_type":"4"}},{"id":3180691,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-04-07T12:26:15.000Z","date":"2020-04-07","kind":"disposition_to_issuer","acquired":false,"shares":20645,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. (\"Gilead\") and Toro Merger Sub, Inc. (\"Purchaser\") (the \"Merger\"), upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the \"Offer to Purchase\") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which provided for vesting over a three-year period as follows: 1/36th of the shares subject to the option vest in a series of 36 successive equal monthly installments beginning on the date of the closing of the Issuer's initial public offering, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $1,790,798.91, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option."}],"balance_after":0,"derivative":{"exercise_price":8.7575,"expiration_date":"2020-04-26","underlying":"Common Stock","underlying_shares":20645},"source":{"system":"sec-edgar","filing":"0001209191-20-023722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919120023722/doc4.xml","form_type":"4"}},{"id":3489685,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T18:17:56.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":10322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the one-year anniversary of the grant date, subject to Reporting Person's continuous service on such date."}],"balance_after":10322,"derivative":{"exercise_price":10.81,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":10322},"source":{"system":"sec-edgar","filing":"0001209191-19-037274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919119037274/doc4.xml","form_type":"4"}},{"id":3801178,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":8552024,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":412583},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801177,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":6702213,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":323341},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801176,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":361829},"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801175,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":453395,"price":15,"value":6800925.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":1623405,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801174,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":412583,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":1170010,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801173,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":323341,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":685170,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3801172,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":6,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":7,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:36:20.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":361829,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are held directly by Clarus Lifesciences III, L.P. (\"Clarus III\"). Clarus Ventures III GP, L.P. (\"Clarus III GP\") is the sole general partner of Clarus III. Clarus Ventures III, LLC (\"Clarus III GP LLC\") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the \"Managing Members\"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein."}],"balance_after":361829,"source":{"system":"sec-edgar","filing":"0001209191-18-053534","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431403/000120919118053534/doc4.xml","form_type":"4"}},{"id":3878867,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1922682},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878866,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":755780,"ownership":{"direct":false,"nature":"See foonote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":755780},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878865,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":938489,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":938489},"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878864,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"purchase","acquired":true,"shares":200000,"price":16,"value":3200000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3816951,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878863,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3616951,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878862,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":755780,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":1694269,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878861,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":15491,"kind":"organization","name":"Clarus Lifesciences III, L.P.","position":1,"cik":"0001597143","reported_name":"Clarus Lifesciences III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15492,"kind":"organization","name":"Clarus Ventures III GP, L.P.","position":2,"cik":"0001620148","reported_name":"Clarus Ventures III GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163261,"kind":"organization","name":"Clarus Ventures III, LLC","position":3,"cik":"0001664942","reported_name":"Clarus Ventures III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":4,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":5,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":6,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":7,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74247,"kind":"person","name":"Requadt Scott","position":8,"cik":"0001664852","reported_name":"Requadt Scott","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":9,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:14:14.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":938489,"ownership":{"direct":false,"nature":"See foonote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":938489,"source":{"system":"sec-edgar","filing":"0001209191-18-040426","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040426/doc4.xml","form_type":"4"}},{"id":3878860,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-02T17:13:00.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1922682},"source":{"system":"sec-edgar","filing":"0001209191-18-040424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040424/doc4.xml","form_type":"4"}},{"id":3878859,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2018-07-02T17:13:00.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":755780,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":755780},"source":{"system":"sec-edgar","filing":"0001209191-18-040424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040424/doc4.xml","form_type":"4"}},{"id":3878858,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2018-07-02T17:13:00.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":938489,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":938489},"source":{"system":"sec-edgar","filing":"0001209191-18-040424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040424/doc4.xml","form_type":"4"}},{"id":3878857,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:13:00.000Z","date":"2018-07-02","kind":"purchase","acquired":true,"shares":200000,"price":16,"value":3200000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3816951,"source":{"system":"sec-edgar","filing":"0001209191-18-040424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040424/doc4.xml","form_type":"4"}},{"id":3878856,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:13:00.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":1922682,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":3616951,"source":{"system":"sec-edgar","filing":"0001209191-18-040424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040424/doc4.xml","form_type":"4"}},{"id":3878855,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:13:00.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":755780,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":1694269,"source":{"system":"sec-edgar","filing":"0001209191-18-040424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040424/doc4.xml","form_type":"4"}},{"id":3878854,"issuer":{"id":16035,"kind":"organization","name":"Forty Seven, Inc.","symbol":"FTSV"},"owners":[{"id":120765,"kind":"person","name":"HENNER DENNIS","position":1,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T17:13:00.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":938489,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest."}],"balance_after":938489,"source":{"system":"sec-edgar","filing":"0001209191-18-040424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667633/000120919118040424/doc4.xml","form_type":"4"}},{"id":4184776,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":false,"reported_value":1259269.79,"ownership":{"direct":true},"footnotes":[{"field":"reported_value","element":"transactionTotalValue","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The amount reported in column 5 is the principal amount of Reporting Person's Convertible Promissory Note (the \"Note\").  The outstanding principal and accrued interest of the Note automatically converted into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the Issuer's IPO upon the closing of the IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":180881},"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184775,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":false,"shares":3389105,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date is not relevant to the conversion of these securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3389105},"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184774,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":true,"shares":180881,"price":7,"value":1266167.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":3569986,"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4184773,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":4,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":5,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":6,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":8,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-10-17T18:43:06.000Z","date":"2017-10-16","kind":"exercise","acquired":true,"shares":3389105,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus.  Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"balance_after":3389105,"source":{"system":"sec-edgar","filing":"0001140361-17-038920","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038920/doc1.xml","form_type":"4"}},{"id":4186578,"issuer":{"id":55304,"kind":"organization","name":"Venus Concept Inc.","symbol":"VERO"},"owners":[{"id":15989,"kind":"organization","name":"Clarus Lifesciences II, L.P.","position":1,"cik":"0001431443","reported_name":"Clarus Lifesciences II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15990,"kind":"organization","name":"Clarus Ventures II GP, L.P.","position":2,"cik":"0001431439","reported_name":"Clarus Ventures II GP, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163523,"kind":"organization","name":"Clarus Ventures II, LLC","position":3,"cik":"0001431437","reported_name":"Clarus Ventures II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":138235,"kind":"person","name":"Simon Nicholas","position":4,"cik":"0001431403","reported_name":"Simon Nicholas","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160424,"kind":"person","name":"LIPTAK ROBERT","position":5,"cik":"0001252523","reported_name":"LIPTAK ROBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139654,"kind":"person","name":"GALAKATOS NICHOLAS","position":6,"cik":"0001252522","reported_name":"GALAKATOS NICHOLAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":7,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":160423,"kind":"person","name":"WHEELER KURT","position":8,"cik":"0001252525","reported_name":"WHEELER KURT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2017-10-13T19:04:52.000Z","date":"2017-10-11","kind":"other","acquired":true,"price":1259269.79,"reported_value":1259269.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were originally acquired from the Issuer on September 6, 2017; however, the conversion price was set upon the pricing of the Issuer's Initial Public Offering (the \"IPO\")."},{"field":"reported_value","element":"transactionTotalValue","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The outstanding principal and accrued interest of the Note automatically converts into shares of the Issuer's Common Stock at the price per share available to the public as set forth in the final prospectus related to the IPO upon the closing of the IPO; if not so converted, the Note has a maturity date of September 6, 2018, at which time it will automatically convert into shares of the Issuer's capital stock."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"The amount reported represents the principal amount of the Reporting Person's Convertible Promissory Note (the \"Note\") only. Accrued interest of 5% per year based on the actual number of days outstanding through the conversion date will also convert."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The convertible promissory note is directly held by Clarus Lifesciences II, L.P. (\"Clarus\"). Clarus Ventures II GP, L.P. (the \"GPLP\"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus. Clarus Ventures II, LLC (the \"GPLLC\"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of he GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest."}],"derivative":{"exercise_price":7,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001140361-17-038670","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1431443/000114036117038670/doc1.xml","form_type":"4"}},{"id":4592724,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":182015,"kind":"organization","name":"MPM BIOVENTURES III LLC","position":1,"cik":"0001249147","reported_name":"MPM BIOVENTURES III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":120765,"kind":"person","name":"HENNER DENNIS","position":2,"cik":"0001249153","reported_name":"HENNER DENNIS","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182016,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC","position":3,"cik":"0001249141","reported_name":"MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182017,"kind":"organization","name":"MPM BIOVENTURES III GMBH & CO. Beteiligungs KG","position":4,"cik":"0001249133","reported_name":"MPM BIOVENTURES III GMBH & CO. Beteiligungs KG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182018,"kind":"organization","name":"MPM BIOVENTURES III PARALLEL FUND, L.P.","position":5,"cik":"0001249063","reported_name":"MPM BIOVENTURES III PARALLEL FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182019,"kind":"organization","name":"MPM BIOVENTURES III GP L.P.","position":6,"cik":"0001249143","reported_name":"MPM BIOVENTURES III GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182020,"kind":"organization","name":"MPM BIOVENTURES III L.P.","position":7,"cik":"0001173408","reported_name":"MPM BIOVENTURES III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182021,"kind":"organization","name":"MPM BIOVENTURES III-QP L.P.","position":8,"cik":"0001173409","reported_name":"MPM BIOVENTURES III-QP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}},{"id":182022,"kind":"person","name":"STEINMETZ MICHAEL","position":9,"cik":"0001166285","reported_name":"STEINMETZ MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% stockholder"}}],"security":"Common Stock","published_at":"2016-09-29T18:04:02.000Z","date":"2016-09-27","kind":"other","acquired":false,"shares":1229902,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by the reporting persons, without consideration to their respective limited partners and members."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were distributed as follows: 1,023,819 shares by MPM Bioventures III-QP, L.P. (\"BV III QP\"), 68,835 shares by MPM BioVentures III, L.P (\"BV III\"), 19,815 shares by MPM Asset Management Investors 2003 BVIII LLC (\"AM 2003\"), 30,911 shares by MPM BioVentures III Parallel Fund, L.P. (\"BV Parallel\") and 86,522 shares by MPM BioVentures III GmbH & Co. Beteiligungs KG (\"BV KG\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by the reporting persons, without consideration to their respective limited partners and members."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The shares are held as follows: 2,047,635 shares by BV III QP, 137,671 shares by BV III, 39,630 shares by AM 2003, 61,823 shares by BV Parallel and 173,045 shares by BV KG."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MPM BioVentures III GP, L.P. (\"MPM III GP\") and MPM BioVentures III LLC (\"MPM III LLC\") are the direct and indirect general partners of BV III QP, BV III, BV Parallel and BV KG.  Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are members of MPM III LLC and AM 2003.  Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein."}],"balance_after":2459804,"source":{"system":"sec-edgar","filing":"0001209191-16-143184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1166285/000120919116143184/doc4.xml","form_type":"4"}}]}